BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shiffman ML. Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation. Liver Transpl. 2003;9:S14-S20. [PMID: 14586890 DOI: 10.1053/jlts.2003.50254] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Furuta K, Sato S, Yamauchi T, Kakumu S. Changes in intrahepatic gene expression profiles from chronic hepatitis to hepatocellular carcinoma in patients with hepatitis C virus infection. Hepatology Research 2008;38:673-82. [DOI: 10.1111/j.1872-034x.2008.00328.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
2 Alberti A, Benvegnù L, Boccato S, Ferrari A, Sebastiani G. Natural history of initially mild chronic hepatitis C. Digestive and Liver Disease 2004;36:646-54. [DOI: 10.1016/j.dld.2004.06.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
3 Schreibman IR, Bejarano P, Martinez EJ, Regev A. Very late recurrence of hepatocellular carcinoma after liver transplantation: case report and literature review. Transplant Proc. 2006;38:3140-3143. [PMID: 17112921 DOI: 10.1016/j.transproceed.2006.08.095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
4 Campbell MS. Hepatitis C: who should be treated? Pharmacoepidemiol Drug Saf 2006;15:77-9. [PMID: 16447299 DOI: 10.1002/pds.1158] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Bozorgzadeh A, Orloff M, Abt P, Tsoulfas G, Younan D, Kashyap R, Jain A, Mantry P, Maliakkal B, Khorana A, Schwartz S. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl. 2007;13:807-813. [PMID: 17539001 DOI: 10.1002/lt.21054] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
6 Lowry DJ, Ryan JD, Ullah N, Kelleher TB, Crowe J. Hepatitis C management: the challenge of dropout associated with male sex and injection drug use. Eur J Gastroenterol Hepatol 2011;23:32-40. [PMID: 21048503 DOI: 10.1097/MEG.0b013e3283414122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Lau DT, Luxon BA, Xiao SY, Beard MR, Lemon SM. Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. Hepatology 2005;42:273-81. [PMID: 15986378 DOI: 10.1002/hep.20767] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 2.8] [Reference Citation Analysis]
8 Verma M. Biomarkers for risk assessment in molecular epidemiology of cancer. Technol Cancer Res Treat 2004;3:505-14. [PMID: 15453816 DOI: 10.1177/153303460400300512] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
9 Guidi M, Muratori P, Granito A, Muratori L, Pappas G, Lenzi M, Bianchi FB. Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. Aliment Pharmacol Ther. 2005;22:943-949. [PMID: 16268968 DOI: 10.1111/j.1365-2036.2005.02679.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
10 Lau DT, Fish PM, Sinha M, Owen DM, Lemon SM, Gale M. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology. 2008;47:799-809. [PMID: 18203148 DOI: 10.1002/hep.22076] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
11 Schmilovitz-Weiss H, Cohen M, Pappo O, Sulkes J, Braun M, Tur-Kaspa R, Ben-Ari Z. Serum globulin levels in predicting the extent of hepatic fibrosis in patients with recurrent post-transplant hepatitis C infection. Clin Transplant. 2007;21:391-397. [PMID: 17488390 DOI: 10.1111/j.1399-0012.2007.00657.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
12 Maluf DG, Archer KJ, Villamil F, Stravitz RT, Mas V. Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression. Expert Review of Gastroenterology & Hepatology 2014;4:445-58. [DOI: 10.1586/egh.10.39] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
13 Örmeci N, Erdem H. Basic answers to complicated questions for the course of chronic hepatitis C treatment. Expert Rev Gastroenterol Hepatol 2012;6:371-82. [PMID: 22646258 DOI: 10.1586/egh.12.16] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World J Gastroenterol 2018; 24(13): 1478-1485 [PMID: 29632428 DOI: 10.3748/wjg.v24.i13.1478] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
15 Gigi E, Raptopoulou-Gigi M, Kalogeridis A, Masiou S, Orphanou E, Vrettou E, Lalla TH, Sinakos E, Tsapas V. Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease. J Viral Hepat. 2008;15:145-154. [PMID: 18184198 DOI: 10.1111/j.1365-2893.2007.00908.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.4] [Reference Citation Analysis]
16 Aroucha D, do Carmo R, Moura P, Silva J, Vasconcelos L, Cavalcanti M, Muniz M, Aroucha M, Siqueira E, Cahú G, Pereira L, Coêlho M. High tumor necrosis factor-α/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C. Cytokine 2013;62:421-5. [DOI: 10.1016/j.cyto.2013.03.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
17 Proell V, Mikula M, Fuchs E, Mikulits W. The plasticity of p19 ARF null hepatic stellate cells and the dynamics of activation. Biochim Biophys Acta 2005;1744:76-87. [PMID: 15878400 DOI: 10.1016/j.bbamcr.2004.12.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 7.3] [Reference Citation Analysis]
19 Holmström M, Nangarhari A, Öhman J, Duberg AS, Majeed A, Aleman S. Long-term liver-related morbidity and mortality related to chronic hepatitis C virus infection in Swedish patients with inherited bleeding disorders. Haemophilia 2016;22:e494-501. [PMID: 27704656 DOI: 10.1111/hae.13020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
20 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms20061358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 19.7] [Reference Citation Analysis]
21 Komolmit P, Charoensuk K, Thanapirom K, Suksawatamnuay S, Thaimai P, Chirathaworn C, Poovorawan Y. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial. PLoS One 2017;12:e0174608. [PMID: 28376103 DOI: 10.1371/journal.pone.0174608] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
22 Olsen DB, Eldrup AB, Bartholomew L, Bhat B, Bosserman MR, Ceccacci A, Colwell LF, Fay JF, Flores OA, Getty KL, Grobler JA, LaFemina RL, Markel EJ, Migliaccio G, Prhavc M, Stahlhut MW, Tomassini JE, MacCoss M, Hazuda DJ, Carroll SS. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 2004;48:3944-53. [PMID: 15388457 DOI: 10.1128/AAC.48.10.3944-3953.2004] [Cited by in Crossref: 172] [Cited by in F6Publishing: 73] [Article Influence: 9.6] [Reference Citation Analysis]
23 Tian XF, Fan XG, Zhang Y, Huang Y, Dai H, Ying RS. Procuration and identification of bacteria in paraffin-embedded liver tissues of hepatocellular carcinoma by laser-assisted microdissection technique. APMIS. 2008;116:10-15. [PMID: 18254774 DOI: 10.1111/j.1600-0463.2008.00739.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]